Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the real-world efficacy and safety of ixazomib,
lenalidomide, or ixazomib in combination with lenalidomide as maintenance therapy in patients
with newly diagnosed multiple myeloma in China.
Phase:
Phase 4
Details
Lead Sponsor:
Peking Union Medical College Hospital
Collaborators:
Beijing Chao Yang Hospital Beijing Jishuitan Hospital Jilin Provincial Tumor Hospital Peking University First Hospital Peking University Third Hospital Shanxi Dayi Hospital Xuanwu Hospital, Beijing